Dabigatran Etexilate (Pradaxa®) for the Primary Prevention of Venous Thromboembolic Events after Total Hip/Knee Replacement

Assessment Status NCPE Assessment Process Complete
HTA ID -
Drug Dabigatran
Brand Pradaxa®
Indication For the Primary Prevention of Venous Thromboembolic Events in Adult Patients who have undergone Total Hip Replacement or Total Knee Surgery.
Assessment Process
Full submission received from Applicant 01/07/2008
NCPE assessment completed 01/09/2008
NCPE assessment outcome Reimbursement recommended